Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd

18.06.2012 – 21:20
Three-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once-Daily Demonstrates Faster and Deeper Responses Compared With Imatinib 400 mg in Patients With Newly Diagnosed Philadelphia+ Chronic Myeloid Leukaemia in Chronic Phase
Paris (ots/PRNewswire) - Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced results from the 3-year follow-up of the DASISION trial, which show that first-line treatment with SPRYCEL(R) 100 mg results infaster ...
mehr
03.04.2009 – 11:46
Long-Term Tolerability and Safety Data of ABILIFY(R) in Combination Treatment for Patients With Bipolar I Disorder
Florence, Italy (ots/PRNewswire) - - Results Presented Today at the Annual Congress of the World Psychiatric Association (WPA) ABILIFY(R) (aripiprazole), when used in combination with lithium or valproate, is a generally well-tolerated long-term treatment for patients with Bipolar I Disorder, who are ...
mehr
08.04.2008 – 09:14
Bristol-Myers Squibb and Otsuka Receive European Marketing Authorisation for ABILIFY(R) in the Treatment and Prevention of Moderate to Severe Manic Episodes in Bipolar I Disorder
Paris, and Uxbridge, England (ots/PRNewswire) - The European Commission has granted marketing authorisation for ABILIFY(R) (aripiprazole) in the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly ...
mehr
22.02.2008 – 17:29
Bristol-Myers Squibb and Otsuka Receive Positive CHMP Opinion for ABILIFY(R) (aripiprazole) in Bipolar I Disorder
Paris and Uxbridge, England (ots/PRNewswire) - Bristol-Myers Squibb (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion on the Marketing Authorisation Application ...
mehr
19.03.2007 – 09:05
84 Percent of Psychiatrists Surveyed Rank Weight Gain or Metabolic Impact as the Most Problematic Effect of Antipsychotic Treatment(1)
Madrid (ots/PRNewswire) - - New Survey Indicates There is Room for Improvement in Physical Health Management Strategies for People Living With Schizophrenia New data presented at the 15th European Congress of Psychiatry (AEP) indicates that the impact of weight gain and metabolic abnormalities associated ...
mehr

Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd

Three-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once-Daily Demonstrates Faster and Deeper Responses Compared With Imatinib 400 mg in Patients With Newly Diagnosed Philadelphia+ Chronic Myeloid Leukaemia in Chronic Phase

Long-Term Tolerability and Safety Data of ABILIFY(R) in Combination Treatment for Patients With Bipolar I Disorder

Bristol-Myers Squibb and Otsuka Receive European Marketing Authorisation for ABILIFY(R) in the Treatment and Prevention of Moderate to Severe Manic Episodes in Bipolar I Disorder

Bristol-Myers Squibb and Otsuka Receive Positive CHMP Opinion for ABILIFY(R) (aripiprazole) in Bipolar I Disorder

84 Percent of Psychiatrists Surveyed Rank Weight Gain or Metabolic Impact as the Most Problematic Effect of Antipsychotic Treatment(1)